Nyxoah S.A.
NASDAQ:NYXHMedical - Instruments & Supplies
+$0.02 today
- Market cap
- $87.89M
- Beta
- 0.89
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$1.99
Volume 0.17M
Average 0.22M
NYXH Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Nyxoah S.A.NASDAQ: NYXH
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow declines year over year
Q1 FY2026 financing cash flow of €369.4K (cash outflow) fell 49.4% year over year, ahead of the -50.0% change in trailing-twelve-month financing cash flow.
Context
- Financing cash flow amounted to 387.1% of revenue in FY2025, down 1325.8 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -49.4% holds above the trailing-twelve-month pace of -50.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
EUR · from the cash flow
- Latest · FY2025
- 38.79M EUR
- Year-over-year change
- -49.9%
- 4-year CAGR
- -15.6%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 38.79M | -49.9% |
| FY2024 | 2024-12-31 | 77.44M | +359.4% |
| FY2023 | 2023-12-31 | 16.86M | +1815.0% |
| FY2022 | 2022-12-31 | (983K) | -101.3% |
| FY2021 | 2021-12-31 | 76.47M | — |
Financing Cash Flow vs competitors
How NYXH compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -50.0% is the 7th highest of 9, against a peer median of +8.3%.
- Financing cash flow amounts to 236.0% of revenue for NYXH, versus a peer median of 22.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $215.52M USD | +89700.8% | +652.5% | 385.8% | |
| LTM Mar 2026 | $164.7M USD | +23.8% | +468.8% | 26649.8% | |
| LTM Mar 2026 | $82.13M USD | -42.0% | — | — | |
| LTM Mar 2026 | €38.51M EUR | -50.0% | — | 236.0% | |
| LTM Mar 2026 | $27.87M USD | +110.1% | -36.8% | 96.4% | |
| LTM Mar 2026 | $24.27M USD | — | -36.0% | 21.3% | |
| LTM Mar 2026 | $22.27M USD | +481.2% | -83.6% | 19.7% | |
| LTM Mar 2026 | $11.3M USD | -7.2% | +457.4% | 7.4% | |
| LTM Mar 2026 | $9.22M USD | -61.7% | +31.0% | 24.6% | |
| LTM Mar 2026 | $89.76K USD | -60.5% | — | 0.2% | |
| Peer median (excluding NYXH) | — | +8.3% | +31.0% | 22.9% | |
Competitors are the stored peer set for NYXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.64M) | (30.06M) | (44.66M) | (56.43M) | (90.05M) |
| Depreciation & Amortization | 1.66M | 1.93M | 2.36M | 2.72M | 4.48M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.27M | 2.7M | 2.61M | 3.97M | 0 |
| Change in Working Capital | (1.14M) | 86K | (3.49M) | 2.96M | 5.37M |
| Accounts Receivables | (2.52M) | 7K | (1.54M) | (751K) | (2.14M) |
| Inventory | (291K) | (536K) | (2.43M) | (1.4M) | 55.98K |
| Accounts Payables | 0 | 0 | 0 | 0 | 7.45M |
| Other Working Capital | 1.67M | 615K | 479K | 5.11M | 0 |
| Other Non-Cash Items | (2.49M) | (3.42M) | (1.6M) | (2.44M) | 12.7M |
| Operating Cash Flow | (25.34M) | (28.76M) | (44.78M) | (49.23M) | (67.5M) |
| Capital Expenditures | (11.82M) | (16.35M) | (10.96M) | (6.07M) | (804.7K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 3K |
| Purchases of Investments | 0 | (102.62M) | (80.02M) | (97.83M) | (42.03M) |
| Sales of Investments | 0 | 28.91M | 120.68M | 85.31M | 71.97M |
| Other Investing Activities | (10.35M) | (15.35M) | (6.15M) | (2.64M) | 0 |
| Investing Cash Flow | (11.82M) | (89.95M) | 32.01M | (16.33M) | 26.17M |
| Debt Repayment | (863K) | (1.07M) | (1.24M) | 8.48M | 21.19M |
| Common Stock Issued | 77.73M | 255K | 18.34M | 69.72M | 20.86M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (393K) | (167K) | (243K) | (758K) | (3.26M) |
| Financing Cash Flow | 76.47M | (983K) | 16.86M | 77.44M | 38.79M |
| Effect of Forex Changes | 3.89M | 2.06M | (369K) | 688K | 2.41M |
| Net Change in Cash | 43.21M | (117.62M) | 3.72M | 12.58M | (130.69K) |
| Free Cash Flow | (37.15M) | (45.11M) | (55.74M) | (55.3M) | (68.3M) |
Nyxoah S.A.
NASDAQ:NYXH
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.